- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01802710
Clinical Improvement and in Quality of Life-Functional Dyspepsia-
Influence of the Combined Psychological and Medical Treatment in the Improvement of Symptoms and Quality of Life in Patients With Functional Dyspepsia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients were recruited from the digestive services of Galdakao-Usansolo and Basurto hospitals. They were randomly allocated to the control or experimental group. 82 patients were included in the control group and 76 in the experimental group.
Regarding the intervention, the treatment of the control group was a conventional (medical) intervention. It was focused on the most bothersome symptom. Prokinetic (for example cinitapride) or antisecretory agent (for example omeprazole) was prescribed in standard dose. Experimental group received the combined intervention (medical plus psychological intervention). The psychological support consisted of ten weekly sessions, which the first 8 were in group and the last 2 were individuals. In those sessions the patients received a) an information session to increase the patients' knowledge of functional dyspepsia; b) a Beck's cognitive-behavioural therapy focused on modifying the influence of some cognitive issues to gastrointestinal symptoms; c) and progressive-muscle relaxation according to Jacobson, with the aim to provide the ability to relax in certain stress situations. This technique was created for reducing anxiety by alternately tensing and relaxing the muscles.
All the patients completed all the self questionnaires at baseline (t0), at the end of the treatment (T1) and at six months follow up (T2). The health related quality of life was assessed by the Dyspepsia Related Health Scale (DRHS), and anxiety and depression were assessed by the Hospital Anxiety and Depression Scale (HADS). Finally, the subjective clinical improvement was also considered and it was measured by a question about how they feel in regard to the functional dyspepsia, with five alternatively responses (a) Much better, b) quite a lot better, c) somewhat better, d) about the same, e) somewhat worse, f) quite a lot worse, g) much worse).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Bizkaia
-
Usansolo, Bizkaia, Spain, 48960
- Galdakao-Usansolo Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- to have chronic upper abdominal symptoms consistent with ROME III criteria for functional dyspepsia
- to have an endoscopy to exclude structural organic causes at the time of the recruitment
Exclusion Criteria:
- to have any organic pathology that could explain the dyspeptic symptoms
- to be using non-steroidal anti-inflammatory drugs (NSAIDs)
- to suffer physical or psychological impairments preventing them from properly completing the questionnaires
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Psychological support
Ten weekly sessions, which the first 8 were in group and the last 2 were individuals.
It consists on a) an informational session; b) Beck's cognitive-behavioural therapy; and c) progressive-muscle relaxation according to Jacobson
|
|
Active Comparator: No psychological support
Patients of this group only received the conventional medical treatment, not receiving any psychological support
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS)
Time Frame: Participants will be followed at the recruit moment (t0) after treatment (t1) and six months after treatment (t2)
|
The Dyspepsia Related Health Scale (DRHS) is a self-reported dyspepsia-specific questionnaire that consists of four scales: severity of common symptoms, pain intensity, pain disability, and satisfaction with dyspepsia-related health.
The score, for each scale, ranges between 0 and 100, with 0 representing the most severe situation and 100 the least severe.
It also yields a global score that ranges from 0 to 100, with higher scores indicating less severe dyspepsia.
The adapted and validated Spanish version of this questionnaire is known as QoL-PEI (Quality of Life in relation to Stomach and Intestinal Problems Questionnaire).
Its reliability was found to be satisfactory (Cronbach's alpha 0.92).
Its factorial analysis confirmed the four scales found by the DRHS but added a global score scale.
The convergent validity was moderate (0.54).
|
Participants will be followed at the recruit moment (t0) after treatment (t1) and six months after treatment (t2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective Clinical Improvement
Time Frame: Subjective clinical improvement it is measured after treatment (t1) and six months after treatment (t2)
|
Subjective clinical improvement was measured by a question about how patients feel in regard to the functional dyspepsia ("In relation to functional dyspepsia, how would you rate your health now?
a)much better; b) quite a lot better; c) somewhat better; d) about the same; e) somewhat worse; f) quite a lot worse; g) much worse
|
Subjective clinical improvement it is measured after treatment (t1) and six months after treatment (t2)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital Anxiety and Depression Scale
Time Frame: Participants will be followed at the recruit moment (t0) after treatment (t1) and six months after treatment (t2)
|
It is a 14-item measure: 7 items evaluate depression (the HADS-D subscale) and 7 evaluate anxiety (the HADS-A subscale).
For each subscale items range from 0 to 21.
A subscale score of 0-7 indicates the absence of anxiety or depression; a score of 8-10 indicates a possible case of anxiety or depression; and a score of 11 or higher indicates the presence of anxiety or depression.
It has been adapted and validated in a Spanish population
|
Participants will be followed at the recruit moment (t0) after treatment (t1) and six months after treatment (t2)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Victor Manuel Orive, Doctor, Basurto University Hospital
- Study Chair: Jose Luis Cabriada, Doctor, Hospital Galdakao-Usansolo
- Study Chair: Aitor Orive, Doctor, Hospital Galdakao-Usansolo
- Study Chair: Begoña Matellanes, Psychology, University of Deusto
- Study Chair: Maria Josefa Ulloa, Nurse, Basurto University Hospital
- Study Chair: Jesus Angel Padierna, Doctor, Hospital Galdakao-Usansolo
- Study Chair: Antonio Escobar, Doctor, Basurto University Hospital
- Study Chair: Antonio Bernal, Doctor, Hospital Galdakao-Usansolo
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2008111005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychogenic Dyspepsia
-
Dartmouth-Hitchcock Medical CenterCompletedDepression | Non-Epileptic Seizure | Psychogenic Non-Epileptic Seizure | Psychogenic SeizureUnited States
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedPsychogenic Non-Epileptic SeizureMexico
-
All India Institute of Medical Sciences, New DelhiUnknownEEG, Psychogenic Non Epileptic Events
-
Central Hospital, Nancy, FranceCompletedPsychogenic Non-epileptic SeizuresFrance
-
Central Hospital, Nancy, FranceDr Coraline HINGRAY; Pr Raymund SCHWAN; Dr Vincent LAPREVOTE; Dr Jean Pierre VIGNAL and other collaboratorsUnknownPsychogenic Non Epileptic SeizureFrance
-
University Hospital, BordeauxCompletedPsychogenic Nonepileptic Seizures (PNESs)France
-
Brain SentinelUnknownEpilepsy, Motor Partial | Psychogenic SeizuresUnited States
-
Brigham and Women's HospitalAmerican Academy of NeurologyCompletedPsychogenic Non-epileptic Seizures, Motivational InterviewingUnited States
-
King Chulalongkorn Memorial HospitalRecruiting
-
Wuhan Central HospitalNot yet recruiting
Clinical Trials on No intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
Medical Corps, Israel Defense ForceUnknownMusculoskeletal Disorders | Upper Extremity Pain ChronicIsrael